The fascinating thing is that the CEO has reduced the share dilution by an order of magnitude over the previous group of sc.. artists who awarded themselves huge blocks of shares. My sense is that we are in a critical moment for the company in which there could well be a patent on the incredible N-Assay technology and if so we then have to see where this goes. I don't think we are dealing with Pipes at this point in terms of operating revenue. That does not mean there is no possibility of that occurring for special expensive projects. If there is a patent issued for the N-Assay (and given the Ebola pressure maybe there could even be an accelerated time frame) then I think the activity moves into a new dimension. My point earlier to which a few apparently "sensitive" people objected is that the potential is incredible, the outcomes are unknown, the technology is real, the needs are great, the risks are unavoidable and in my judgment the company is doing everything it can to succeed.